Also categorized in Business of Medicine:
Freestanding Emergency Departments May Increase Out-of-Pocket Spending for Patients
x hide permanently

Study: Atezolizumab Extends Disease-Free Survival by More than One-Third in Subset of Patients with Lung Cancer

Pharmacy Times

Image: Pixaby

pharmacytimes.com

Pivotal phase 3 data to be presented at the American Society of Clinical Oncology (ASCO) 2021 Annual Meeting found that atezolizumab (Tecentriq) extended disease-free survival (DFS) by more than one-third in patients with programmed death-ligand 1 (PD-L1)-positive, resectable early-stage lung cancer.

Atezolizumab is the first and only oncology immunotherapy to show positive phase 3 results in the adjuvant lung cancer setting, according to a Genentech press release. The lung cancer space is in desperate need of a new adjuvant treatment option for the approximately 50% of patients who currently experience cancer recurrence following surgery.

Atezolizumab ...